Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Summary

The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.

Timeline

Start

2026-02-11

Primary completion

2028-10-23

Completion

2032-02-28

Drugs

Indications